2019

Peer Reviewed Publications in Print or Other Media

Biomarker-driven strategy for MCL1 Inhibition in T-cell lymphomas

Raphael Koch, Amanda L. Christie, Jennifer L. Crombie, Adam C. Palmer, Deborah Plana, Kay Shigemori, Sara N. Morrow, Alexandria Van Scoyk, Wenchao Wu, Elizabeth A. Brem, J. Paul Secrist, Lisa Drew, Alwin G. Schuller, Justin Cidado, Anthony Letai, and David M. Weinstock. "Biomarker-driven strategy for MCL1 Inhibition in T-cell lymphomas." The American Society of Hematology. Volume 133, number 6. 7 February 2019.

Bruton tyrosine kinase degradation as a therapeutic strategy for cancer

Dennis Dobrovolsky, Eric S. Wang, Sara Morrow, Catharine Leahy, Tyler Faust, Radosław P. Nowak, Katherine A. Donovan, Guang Yang, Zhengnian Li, Eric S. Fischer, Steven P. Treon, David M. Weinstock, and Nathanael S. Gray. "Bruton tyrosine kinase degradation as a therapeutic strategy for cancer." The American Society of Hematology. 133(9):952-961. doi: 10.1182/blood-2018-07-862953. 2019 Feb 28.

Mechanisms of lymphoma clearance induced by high-dose alkylating agents

Chen Lossos, Yunpeng Liu, Kellie E. Kolb, Amanda L. Christie, Alexandria Van Scoyk, Sanjay M. Prakadan, Kay Shigemori, Kristen E. Stevenson, Sara Morrow, Olivia D. Plana, Cameron Fraser, Kristen L. Jones, Huiyun Liu, Christian P. Pallasch, Rebecca Modiste, Quang-De Nguyen, Jeffrey W. Craig, Elizabeth A. Morgan, Francisco Vega, Jon C. Aster, Kristopher A. Sarosiek, Alex K. Shalek, Michael T.   Hemann, and David M. Weinstock "Mechanisms of lymphoma clearance induced by high-dose alkylating agents." American Association for Cancer Research. 2019;9 1-18. April 30, 2019.

Next- Generation characterization of the Cancer Cell Line Encyclopedia

Ghandi M, Huang FW, Jané-Valbuena J, Kryukov GV, Lo CC, McDonald ER 3rd, Barretina J, Gelfand ET, Bielski CM, Li H, Hu K, Andreev-Drakhlin AY, Kim J, Hess JM, Haas BJ, Aguet F, Weir BA, Rothberg MV, Paolella BR, Lawrence MS, Akbani R, Lu Y, Tiv HL, Gokhale PC, de Weck A, Mansour AA, Oh C, Shih J, Hadi K, Rosen Y, Bistline J, Venkatesan K, Reddy A, Sonkin D, Liu M, Lehar J, Korn JM,    Porter DA, Jones MD, Golji J, Caponigro G, Taylor JE, Dunning CM, Creech AL, Warren AC, McFarland JM, Zamanighomi M, Kauffmann A, Stransky N, Imielinski M, Maruvka YE, Cherniack AD, Tsherniak A, Vazquez F, Jaffe JD, Lane AA, Weinstock DM, Johannessen CM, Morrissey MP, Stegmeier F, Schlegel R, Hahn WC, Getz G, Mills GB, Boehm JS, Golub TR, Garraway LA, Sellers WR. "Next-Generation Characterization of the Cancer Cell Line Encyclopedia." Nature. 569(7757): 503-508. doi: 10.1038/s41586-019-1186-3. Epub 2019 May 8. 

Chemical, Biological, Radiolological, Nuclear, and Explosive (CBRNE) Science and the CBRNE Science Medical Operations Science Support Expert (CMOSSE)

Coleman, C., Bader, J., Koerner, J., Hrdina, C., Cliffer, K., Hick, J., James, J., Mansoura K., Livinski, A., Nystrom, V., DiCarlo-Cohen, A., Marinessen, J., Wathen, L., Appler, M., Buddemeier, B., Casagrande, R., Estes, D., Byrne, P., Kennedy, M., Jakubowski, A., Case, C., Weinstock, D., Dainiak, N., Hanfling, D., Garrett, L., Grant, N., Dodgen, D., Redlener, I., MacKAY, F., Treber, M., Homer, J., Taylor, P., Miller, A., Korch, G., Hatchett, R. . "Chemical, Biological, Radiological, Nuclear, and Explosive (CBRNE) Science and the CBRNE Science Medical Operations Science Support Expert (CMOSSE)." Disaster Medicine and Public Health Preparedness, 1-16. doi:10.1017/dmp.2018.163

Targeted Inhibition of CD47-SIRPa Requires Fc-FcyR Interactions to Maximize Activity in T-cell Lymphomas

Jain, S., Van Scoyk, A., Morgan, E. A., Matthews, A., Stevenson, K., Newton, G., Powers, F., Autio, A., Louissaint, A., Pontini, G., Aster, J. C., Luscinskas, F. W., & Weinstock, D. M. (2019). "Targeted Inhibition of CD47-SIRPα Requires Fc-FcγR Interactions to Maximize Activity in T-cell Lymphomas." Blood, (),blood.2019001744. Accessed August 06, 2019.